Cost-effectiveness of human papilloma virus vaccination in Iceland
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field OBJECTIVE: To evaluate the likely cost-effectiveness of introducing routine HPV vaccination in Iceland. DESIGN: Prospective cost-effectiveness analysis of human papilloma virus (HPV) vaccin...
Published in: | Acta Obstetricia et Gynecologica Scandinavica |
---|---|
Main Authors: | , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Informa Healthcare
2010
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/96636 https://doi.org/10.3109/00016340903322750 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/96636 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/96636 2023-05-15T16:46:04+02:00 Cost-effectiveness of human papilloma virus vaccination in Iceland Oddsson, Kristjan Johannsson, Jakob Asgeirsdottir, Tinna Laufey Gudnason, Thorolfur Directorate of Health, 170 Seltjarnarnes, Iceland. oddsson@hotmail.com 2010-04-16 http://hdl.handle.net/2336/96636 https://doi.org/10.3109/00016340903322750 en eng Informa Healthcare http://dx.doi.org/10.3109/00016340903322750 Acta Obstet Gynecol Scand. 2009, 88(12):1411-6 1600-0412 19900074 doi:10.3109/00016340903322750 http://hdl.handle.net/2336/96636 Acta obstetricia et gynecologica Scandinavica Child Cohort Studies Cost-Benefit Analysis Female Human papillomavirus 16 Human papillomavirus 18 Humans Iceland Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Uterine Cervical Neoplasms Vaccination Article 2010 ftlandspitaliuni https://doi.org/10.3109/00016340903322750 2022-05-29T08:21:31Z To access publisher full text version of this article. Please click on the hyperlink in Additional Links field OBJECTIVE: To evaluate the likely cost-effectiveness of introducing routine HPV vaccination in Iceland. DESIGN: Prospective cost-effectiveness analysis of human papilloma virus (HPV) vaccination. SETTING AND SAMPLE: Population of 12-year-old girls in the Icelandic population. METHODS: A model was developed, comparing a cohort of all 12-year-old girls alive in year 2006, with or without vaccination. The model was based on the epidemiology of cervical cancer in Iceland and its premalignant stages as well as the costs involved in the treatment of each stage, assuming that the vaccines only prevent infections caused by HPV 16/18 at an efficacy of 95% and participation rate of 90%, no catch-up vaccination, no vaccination of boys and no booster dose needed. All costs were calculated on the basis of the price level of mid-year 2006 with a 3% discount rate. Incremental cost-effectiveness ratio calculations were performed and sensitivity analysis was carried out on factors most relevant for cost-effectiveness. RESULTS: Vaccination costs in excess of savings would be about euro313.000/year. Vaccination would reduce the number of women diagnosed with cervical cancer by almost 9, prevent the death of 1.7 women and result in 16.9 quality-adjusted life years gained annually. The incremental cost-effectiveness ratio was calculated to be about euro18.500/quality-adjusted life year saved. CONCLUSION: HPV vaccination seems to be cost-effective in Iceland, but this was sensitive to various parameters in the model, mainly the discount rate, the price of the vaccines and the need for a booster dose. Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive Acta Obstetricia et Gynecologica Scandinavica 88 12 1411 1416 |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Child Cohort Studies Cost-Benefit Analysis Female Human papillomavirus 16 Human papillomavirus 18 Humans Iceland Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Uterine Cervical Neoplasms Vaccination |
spellingShingle |
Child Cohort Studies Cost-Benefit Analysis Female Human papillomavirus 16 Human papillomavirus 18 Humans Iceland Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Uterine Cervical Neoplasms Vaccination Oddsson, Kristjan Johannsson, Jakob Asgeirsdottir, Tinna Laufey Gudnason, Thorolfur Cost-effectiveness of human papilloma virus vaccination in Iceland |
topic_facet |
Child Cohort Studies Cost-Benefit Analysis Female Human papillomavirus 16 Human papillomavirus 18 Humans Iceland Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Uterine Cervical Neoplasms Vaccination |
description |
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field OBJECTIVE: To evaluate the likely cost-effectiveness of introducing routine HPV vaccination in Iceland. DESIGN: Prospective cost-effectiveness analysis of human papilloma virus (HPV) vaccination. SETTING AND SAMPLE: Population of 12-year-old girls in the Icelandic population. METHODS: A model was developed, comparing a cohort of all 12-year-old girls alive in year 2006, with or without vaccination. The model was based on the epidemiology of cervical cancer in Iceland and its premalignant stages as well as the costs involved in the treatment of each stage, assuming that the vaccines only prevent infections caused by HPV 16/18 at an efficacy of 95% and participation rate of 90%, no catch-up vaccination, no vaccination of boys and no booster dose needed. All costs were calculated on the basis of the price level of mid-year 2006 with a 3% discount rate. Incremental cost-effectiveness ratio calculations were performed and sensitivity analysis was carried out on factors most relevant for cost-effectiveness. RESULTS: Vaccination costs in excess of savings would be about euro313.000/year. Vaccination would reduce the number of women diagnosed with cervical cancer by almost 9, prevent the death of 1.7 women and result in 16.9 quality-adjusted life years gained annually. The incremental cost-effectiveness ratio was calculated to be about euro18.500/quality-adjusted life year saved. CONCLUSION: HPV vaccination seems to be cost-effective in Iceland, but this was sensitive to various parameters in the model, mainly the discount rate, the price of the vaccines and the need for a booster dose. |
author2 |
Directorate of Health, 170 Seltjarnarnes, Iceland. oddsson@hotmail.com |
format |
Article in Journal/Newspaper |
author |
Oddsson, Kristjan Johannsson, Jakob Asgeirsdottir, Tinna Laufey Gudnason, Thorolfur |
author_facet |
Oddsson, Kristjan Johannsson, Jakob Asgeirsdottir, Tinna Laufey Gudnason, Thorolfur |
author_sort |
Oddsson, Kristjan |
title |
Cost-effectiveness of human papilloma virus vaccination in Iceland |
title_short |
Cost-effectiveness of human papilloma virus vaccination in Iceland |
title_full |
Cost-effectiveness of human papilloma virus vaccination in Iceland |
title_fullStr |
Cost-effectiveness of human papilloma virus vaccination in Iceland |
title_full_unstemmed |
Cost-effectiveness of human papilloma virus vaccination in Iceland |
title_sort |
cost-effectiveness of human papilloma virus vaccination in iceland |
publisher |
Informa Healthcare |
publishDate |
2010 |
url |
http://hdl.handle.net/2336/96636 https://doi.org/10.3109/00016340903322750 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://dx.doi.org/10.3109/00016340903322750 Acta Obstet Gynecol Scand. 2009, 88(12):1411-6 1600-0412 19900074 doi:10.3109/00016340903322750 http://hdl.handle.net/2336/96636 Acta obstetricia et gynecologica Scandinavica |
op_doi |
https://doi.org/10.3109/00016340903322750 |
container_title |
Acta Obstetricia et Gynecologica Scandinavica |
container_volume |
88 |
container_issue |
12 |
container_start_page |
1411 |
op_container_end_page |
1416 |
_version_ |
1766036190057725952 |